Physician profile
John J Solomon
NPI 1861529158
$2,127.64
in general payments reported to CMS, 2019-2025
23 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $93.27 · 2021: $522 · 2022: $354 · 2023: $351 · 2024: $219 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $550.30 | 2019-2025 | |
| Novo Nordisk INC | $261.27 | 2019-2023 | Ozempic, Rybelsus, Tresiba |
| Abbott Laboratories | $164.66 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $157.44 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $144.25 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $125.89 | 2021-2022 | |
| Corcept Therapeutics | $87.29 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $80.70 | 2021-2022 | |
| Abbvie INC. | $77.30 | 2021-2025 | |
| Lilly USA, LLC | $76.20 | 2021-2025 | Mounjaro, Zepbound |
| Janssen Scientific Affairs, LLC | $57.82 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.82 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $42.34 | 2025 | Airsupra |
| Esperion Therapeutics, INC. | $35.25 | 2020-2021 | |
| Astellas Pharma US INC | $34.96 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.41 | 2019 | |
| Nestle Healthcare Nutrition INC. | $31.37 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.70 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Amarin Pharma, INC. | $29.27 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $17.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.24 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.